Skip to main content

Conjunctivitis, Allergic

10
Pipeline Programs
4
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
2
2
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
6 programs
2
2
Alcaftadine 0.25%Phase 41 trial
alcaftadine 0.25% ophthalmic solutionPhase 41 trial
AGN-229666Phase 31 trial
AGN-229666Phase 31 trial
Alcaftadine Ophthalmic Solution 0.25%N/A1 trial
+1 more programs
Active Trials
NCT02555761Completed3,423Est. Mar 2018
NCT01987765Completed847Est. Sep 2012
NCT02082262Completed140Est. Jul 2014
+3 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
1
1
BeprevePhase 2/31 trial
MapracoratPhase 21 trial
Active Trials
NCT01289431Completed236Est. Apr 2011
NCT00424398Completed107
Bausch + Lomb
Bausch + LombNJ - Bridgewater
2 programs
1
1
BeprevePhase 2/3
MapracoratPhase 2
Aldeyra Therapeutics
Aldeyra TherapeuticsMA - Lexington
2 programs
1
1
ADX-102 Ophthalmic DropsPhase 21 trial
Reproxalap Ophthalmic SolutionPhase 1/21 trial
Active Trials
NCT03709121Completed70Est. Mar 2019
NCT03012165Completed154Est. May 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieAlcaftadine 0.25%
AbbViealcaftadine 0.25% ophthalmic solution
AbbVieAGN-229666
AbbVieAGN-229666
Bausch HealthBepreve
Aldeyra TherapeuticsADX-102 Ophthalmic Drops
Bausch HealthMapracorat
Aldeyra TherapeuticsReproxalap Ophthalmic Solution
AbbVieAlcaftadine Ophthalmic Solution 0.25%
AbbVieRelestat Ophthalmic Solution 0.05%

Clinical Trials (10)

Total enrollment: 5,501 patients across 10 trials

NCT01732757AbbVieAlcaftadine 0.25%

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

Start: Nov 2012Est. completion: Dec 2012157 patients
Phase 4Completed
NCT01470118AbbViealcaftadine 0.25% ophthalmic solution

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

Start: Oct 2011Est. completion: Dec 2011127 patients
Phase 4Completed
NCT02161146AbbVieAGN-229666

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

Start: Jun 2014Est. completion: Dec 2014240 patients
Phase 3Completed
NCT02082262AbbVieAGN-229666

AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

Start: Mar 2014Est. completion: Jul 2014140 patients
Phase 3Completed
NCT00424398Bausch HealthBepreve

Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

Start: Feb 2007107 patients
Phase 2/3Completed
NCT03012165Aldeyra TherapeuticsADX-102 Ophthalmic Drops

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Start: Dec 2016Est. completion: May 2017154 patients
Phase 2Completed
NCT01289431Bausch HealthMapracorat

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

Start: Feb 2011Est. completion: Apr 2011236 patients
Phase 2Completed
NCT03709121Aldeyra TherapeuticsReproxalap Ophthalmic Solution

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Start: Oct 2018Est. completion: Mar 201970 patients
Phase 1/2Completed
NCT02555761AbbVieAlcaftadine Ophthalmic Solution 0.25%

Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea

Start: Oct 2015Est. completion: Mar 20183,423 patients
N/ACompleted
NCT01987765AbbVieRelestat Ophthalmic Solution 0.05%

Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

Start: Jan 2009Est. completion: Sep 2012847 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.